Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal

Alzheimer's Disease Neuroimaging Initiative

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

OBJECTIVE: To identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC). METHODS: We selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative. Common clinical markers, Alzheimer disease (AD) biomarkers, and neurodegeneration imaging markers were used to compare MCI reverters based on subsequent clinical outcome (i.e., subsequent decline or stable reversion). For independent comparison, findings of the clinical Amsterdam Dementia Cohort are presented. RESULTS: Seventy-seven (10%) out of 757 individuals with MCI reverted to NC and 61 of these individuals had follow-up data available. After 3.2 ± 2.2 years, 16 (24%) progressed to MCI, and 3 (5%) to dementia. Those who declined were older and had a higher amyloid PET burden and higher CSF tau levels. CONCLUSION: In MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline. AD biomarkers may aid in the prognosis of reverting MCI.
Original languageEnglish
Pages (from-to)e2699-e2705
JournalNeurology
Volume92
Issue number23
DOIs
Publication statusPublished - 2019

Cite this

Alzheimer's Disease Neuroimaging Initiative. / Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. In: Neurology. 2019 ; Vol. 92, No. 23. pp. e2699-e2705.
@article{598c233836074305b917450e3b32b6a6,
title = "Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal",
abstract = "OBJECTIVE: To identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC). METHODS: We selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative. Common clinical markers, Alzheimer disease (AD) biomarkers, and neurodegeneration imaging markers were used to compare MCI reverters based on subsequent clinical outcome (i.e., subsequent decline or stable reversion). For independent comparison, findings of the clinical Amsterdam Dementia Cohort are presented. RESULTS: Seventy-seven (10{\%}) out of 757 individuals with MCI reverted to NC and 61 of these individuals had follow-up data available. After 3.2 ± 2.2 years, 16 (24{\%}) progressed to MCI, and 3 (5{\%}) to dementia. Those who declined were older and had a higher amyloid PET burden and higher CSF tau levels. CONCLUSION: In MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline. AD biomarkers may aid in the prognosis of reverting MCI.",
author = "Lisa Vermunt and {van Paasen}, {Alegr{\'i}a J. L.} and Teunissen, {Charlotte E.} and Philip Scheltens and Visser, {Pieter Jelle} and Tijms, {Betty M.} and {Alzheimer's Disease Neuroimaging Initiative}",
year = "2019",
doi = "10.1212/WNL.0000000000007609",
language = "English",
volume = "92",
pages = "e2699--e2705",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "23",

}

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. / Alzheimer's Disease Neuroimaging Initiative.

In: Neurology, Vol. 92, No. 23, 2019, p. e2699-e2705.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal

AU - Vermunt, Lisa

AU - van Paasen, Alegría J. L.

AU - Teunissen, Charlotte E.

AU - Scheltens, Philip

AU - Visser, Pieter Jelle

AU - Tijms, Betty M.

AU - Alzheimer's Disease Neuroimaging Initiative

PY - 2019

Y1 - 2019

N2 - OBJECTIVE: To identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC). METHODS: We selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative. Common clinical markers, Alzheimer disease (AD) biomarkers, and neurodegeneration imaging markers were used to compare MCI reverters based on subsequent clinical outcome (i.e., subsequent decline or stable reversion). For independent comparison, findings of the clinical Amsterdam Dementia Cohort are presented. RESULTS: Seventy-seven (10%) out of 757 individuals with MCI reverted to NC and 61 of these individuals had follow-up data available. After 3.2 ± 2.2 years, 16 (24%) progressed to MCI, and 3 (5%) to dementia. Those who declined were older and had a higher amyloid PET burden and higher CSF tau levels. CONCLUSION: In MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline. AD biomarkers may aid in the prognosis of reverting MCI.

AB - OBJECTIVE: To identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC). METHODS: We selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative. Common clinical markers, Alzheimer disease (AD) biomarkers, and neurodegeneration imaging markers were used to compare MCI reverters based on subsequent clinical outcome (i.e., subsequent decline or stable reversion). For independent comparison, findings of the clinical Amsterdam Dementia Cohort are presented. RESULTS: Seventy-seven (10%) out of 757 individuals with MCI reverted to NC and 61 of these individuals had follow-up data available. After 3.2 ± 2.2 years, 16 (24%) progressed to MCI, and 3 (5%) to dementia. Those who declined were older and had a higher amyloid PET burden and higher CSF tau levels. CONCLUSION: In MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline. AD biomarkers may aid in the prognosis of reverting MCI.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85067213324&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31068481

U2 - 10.1212/WNL.0000000000007609

DO - 10.1212/WNL.0000000000007609

M3 - Article

VL - 92

SP - e2699-e2705

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 23

ER -